Your browser doesn't support javascript.
loading
Remdesivir-associated bradycardia.
Ching, Patrick R; Lee, Calvin.
Affiliation
  • Ching PR; Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA patrickrching@gmail.com.
  • Lee C; Division of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
BMJ Case Rep ; 14(9)2021 Sep 03.
Article in En | MEDLINE | ID: mdl-34479903
ABSTRACT
Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially among those with underlying cardiovascular disease, elderly and using ß-blockers.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bradycardia / COVID-19 Drug Treatment Type of study: Risk_factors_studies Limits: Adult / Aged / Humans / Male Language: En Journal: BMJ Case Rep Year: 2021 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bradycardia / COVID-19 Drug Treatment Type of study: Risk_factors_studies Limits: Adult / Aged / Humans / Male Language: En Journal: BMJ Case Rep Year: 2021 Document type: Article Affiliation country: